Zhengye Biotechnology Holding Limited ZYBT
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $16.64M, -34.8% YoY · Filed Apr 28, 2026
Zhengye Biotechnology Holding Limited (ZYBT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $16.6 million and a net loss of $10.0 million. Free cash flow was $1.8 million. As of Dec 31, 2025 it held $7.4 million in cash and investments and $10.7 million in total debt.
Revenue
$16.64M
-34.8% vs prior year
Net income
$-9.98M
-744.0% vs prior year
Operating cash flow
$1.91M
-66.0% vs prior year
Free cash flow
$1.77M
-53.0% vs prior year
EPS
$0.03
Dividend per share
None
Shares outstanding
47.39M
+3.8% vs prior year
Net cash
$-3.33M
FY 2025
Operating margin
-60.6%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYBT (Nasdaq)
- Incorporated in
- China
- Headquarters
- Jilin
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1975641
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $16.6M | $25.5M |
| Operating income | -$10.1M | $2.3M |
| Net income | -$10.0M | $1.6M |
| Diluted EPS | — | $0.03 |
| Operating cash flow | $1.9M | $5.6M |
| Free cash flow | $1.8M | $3.8M |
| Total assets | $62.4M | $67.6M |
| Total liabilities | $18.6M | $19.3M |
| Stockholders' equity | $35.7M | $38.9M |
| Cash and investments | $7.4M | $2.7M |
| Total debt | $10.7M | $11.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 6, 2026 |
| 6-K | Current report (foreign issuer) | Jul 21, 2026 | Jul 21, 2026 |
| 6-K | Current report (foreign issuer) | Jun 4, 2026 | Jun 4, 2026 |
| 20-F | Annual report (foreign issuer) | Apr 28, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 25, 2026 | Mar 24, 2026 |
| 6-K | Current report (foreign issuer) | Mar 2, 2026 | Feb 27, 2026 |
All 61 Zhengye Biotechnology Holding Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.